

Patient: [REDACTED]  
DOB: [REDACTED] Age: [REDACTED] Gender: [REDACTED]  
Patient Identifiers: [REDACTED]  
Visit Number (FIN): [REDACTED]

Client: [REDACTED]  
Physician: [REDACTED]

ARUP Test Code: 2002653  
Collection Date: 11/21/2016  
Received in lab: 11/23/2016  
Completion Date: 11/27/2016

## Interpretation

Specimen Received  
Specimen Type: Bone Marrow  
Reason for Referral: Pancytopenia; Possible MDS and AML  
Test Performed: FISH, TAML MDS

---

**ABNORMAL FISH RESULTS**  
7cen (D7Z1), 7q31 (D7S486): deletion present

**NORMAL FISH RESULTS**  
5q31 (EGR1): deletion not detected  
11q23 (KMT2A; also known as MLL): rearrangement / deletion not detected

**DIAGNOSTIC IMPRESSION:**  
Fluorescence in situ hybridization (FISH) analysis was performed with the Therapy-Related AML/MDS Panel probes: EGR1, D7Z1, D7S486 and KMT2A (MLL) (Abbott Molecular). 200 interphase cells were scored for each probe combination.

This analysis showed evidence of deletion 7q31 involving the D7S486 locus in 27/200 (13.5 percent) cells scored.

The remaining probes showed normal results.

Deletion 7q is a recurrent abnormality observed in myeloid disorders, including MDS and AML. In the context of therapy-related myeloid neoplasms, this finding may indicate a poor prognosis.

Please correlate this result with clinical and other laboratory findings.

**Reference:**  
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. (Eds.): WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon 2008.

**ISCN:**  
nuc ish(EGR1x2) [200], (D7Z1x2,D7S486x1) [27/200], (KMT2Ax2) [200]

This result has been reviewed and approved by [REDACTED],  
Ph.D., FACMG  
Electronic Signature

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement A: [aruplab.com/CS](http://aruplab.com/CS)



Patient: [REDACTED]  
ARUP Accession: 16-326-139688